Company intelligence / Profile preview
Enesi Pharma
Milton, England, United Kingdomenesipharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Enesi Pharma’s ImplaVax platform has demonstrated that solid-dose vaccines can induce superior or equivalent immune responses to conventional injections in preclinical models and have retained activity under thermostable conditions, potentially eliminating cold chain logistics.
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- VaccineDNA vaccineRNA therapyRecombinant proteinLive biotherapeutic product therapyDevice (drug-device combination)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Imperial College LondonUniversity of OxfordUniversity of AdelaideSementisPublic Health EnglandWalter Reed Army Institute of Research (WRAIR)BARDA
Beyond the preview
Go deeper on Enesi Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enesi Pharma.